Dashboard · Pharmaceuticals stocks · APOLLOHOSP
85
JayScore

Apollo Hospitals Enterprise Limited

APOLLOHOSP Pharmaceuticals
High Conviction Grade A+ 72% confidence
Score computed at ₹8,771.00 · 16 Nov 2026
Research signals 0 positive · 8 cautionary of 8
NSE
JayScore
85
vs
Sector signal
7
85
Apollo Hospitals Enterprise Limited APOLLOHOSP High Conviction
Get notified when this stock's JayScore changes
Free account — score alerts, daily research picks, morning plan and portfolio tracker.
Sign Up Free Sign In
About Apollo Hospitals Enterprise Limited

Apollo Hospitals Enterprise Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹1.23 lakh crore. The company reports ROE of 22.5%, a net profit margin of 8.1%. Revenue grew +20.8% year-over-year. Promoter holding stands at 28.4%, with FII participation at 50.6%.

Pharmaceuticals sector signal: 7/100 — below-average — fewer than 40% of sector peers are trading above their EMA 20.
JayScore 85/100 indicates a strong research signal — multiple technical and fundamental factors are aligned positively. JayScore is a quantitative index — not investment advice. Learn how it's calculated →
JaySense Research View · quantitative signals only · not investment advice
High Conviction

Buying pressure is building (RSI/MACD momentum confirmed). Trading near its strongest price of the year (within 5% of 52-week high). Company earns strong returns on shareholder money (ROE 22.5% — above 15% benchmark). A trend-following indicator is on the bullish side (SuperTrend signal: buy). The whole industry is moving up together (sector — most peers above EMA20). The uptrend is visible even on the weekly chart (longer-term trend confirmed). Price just broke to a 20-day high after a quiet period (tight consolidation breakout — high probability setup). Short-term oscillator is overheated — entering now means chasing (StochRSI above 80, late entry risk). Above-average delivery percentage suggests real buying, not just speculation (delivery 59%). Both short and medium-term trend lines are pointing upward — the trend has momentum (rising EMA20 + EMA50). Foreign institutions have been net buyers for 4 consecutive days — sustained institutional demand (✅ FII buying streak). Approaching its key breakout zone — watch for a volume-backed close above resistance to confirm entry.

Positive Signals
Volume pattern supports the current price move
Sector sentiment is positive — tailwinds present
6 of 9 research signals are converging positively
Watch Points
Fundamental score is weak relative to benchmark
Valuation appears stretched on current metrics
Institutional activity is low or declining
Research Score Insight

Apollo Hospitals Enterprise Limited scores 85/100 (High Conviction Research Signal). The strongest signals are Momentum (13/100) and Trend (11/100). The weakest dimension is Institutional Activity (0/100), which warrants monitoring. This reflects JaySense quantitative research scoring only — not investment advice. Consult a SEBI Registered Investment Adviser before making any investment decision.

Trend 11 Momentum 13 Volume 9 Fundamental 3 Valuation 0 Growth 6 Institutional 0 Sector 7 Risk 6
Research Intelligence Free Account Required
1 positive · 9 risk signals identified 6 / 9 signals converging
ROE of 22.5% — superior return on equity vs sector median
Downtrend active — price has broken below key moving averages
Institutional indicators suggest active accumulation in this price zone
Volatility ratio and momentum signal caution at current levels
Institutional indicators suggest active accumulation in this price zone
Volatility ratio and momentum signal caution at current levels

8 more research signals — available free with a JaySense account

Get Free Access Sign in
Sector & Institutional Activity Free Account Required
Sector Health
7.2000/100
Sector Rank
#3 of 12
FII Activity
Net Buying
FII net buyers ₹840 Cr over last 10 sessions — institutional accumulation in progress
DII activity supportive — domestic funds adding to position

Sector peer rank, FII/DII trend & institutional activity — free with a JaySense account

Get Free Access Sign in
Score Analysis
Trend
11
Weak
Price vs moving averages · trend structure
Momentum
13
Weak
MACD · RSI · rate-of-change
Volume
9
Weak
Volume strength · accumulation vs distribution
Fundamental
3
Weak
Margins · returns · debt ratios
Valuation
0
Weak
PE · PB · multiples vs sector
Growth
6
Weak
Revenue & profit growth YoY
Sector
7
Weak
Sector relative strength vs market
Risk
6
Weak
Volatility · beta · drawdown risk
Institutional
0
Weak
FII / DII participation & block deals
Signal convergence: 6 / 9 dimensions aligned · High convergence
Score Trend (Last 30 Scores)
Fundamentals
Market Cap
₹1.23 L Cr
P/E Ratio
54.52
P/B Ratio
11.56
EPS (TTM)
156.39
ROE
22.5%
ROCE
—
Net Profit Margin
8.1%
Debt / Equity
73.04
Revenue Growth YoY
20.8%
Profit Growth YoY
31.9%
Promoter Holding
28.4%
FII Holding
50.6%
Dividend Yield
0.2%
Company Profile
Apollo Hospitals Enterprise Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹1.23 lakh crore. The company reports ROE of 22.5%, a net profit margin of 8.1%. Revenue grew +20.8% year-over-year. Promoter holding stands at 28.4%, with FII participation at 50.6%.
Corporate Actions
Corporate Actions Source: NSE
Recent History
₹10.00 / share
14 Aug 2026
Dividend
Related Research — Same Sector
Stock Score Signal
AUROPHARMA
Aurobindo Pharma Limited
82 High Conviction
SUNPHARMA
Sun Pharmaceutical Industries Limited
72 High Conviction
CIPLA
Cipla Limited
72 High Conviction
DIVISLAB
Divi's Laboratories Limited
70 High Conviction
GLENMARK
Glenmark Pharmaceuticals Limited
64 Positive Setup
How JaySense scores stocks Full stock screener
Disclaimer: JaySense scores are research outputs based on technical and fundamental signals. They are not buy/sell recommendations and do not constitute investment advice. Past score performance does not guarantee future returns. Please do your own research or consult a SEBI-registered investment advisor before making any investment decision. JaySense is not SEBI-registered. Use this platform for educational and research purposes only.